Inhibrx secures $150M loan facility from Oxford Finance; $100M funded upfront

Inhibrx Biosciences, Inc.

Loan and Security Agreement with Oxford Finance for up to $150M term loan; $100M funded on Jan 13, 2025.
Remaining $50M available at Inhibrx's request and Lenders' sole discretion.
Interest-only payments through Feb 2028; maturity Jan 1, 2030; rate = 1M SOFR + 5.61% (floor 4.34%).
Issued warrants for 140,741 shares at $14.21/exercise price, representing 2% of initial $100M tranche.
Proceeds provide strategic flexibility ahead of expected data readouts for INBRX-109 and INBRX-106 programs.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.